Immutep Ltd (ASX:IMM)

APAC company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - IMM

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - IMM

  • Market CapAUD0.000m
  • SymbolASX:IMM
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINAU000000IMM6

Company Profile

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives most of the revenue from the sale of the products.Immutep Ltd, formerly Prima Biomed Ltd is a biotechnology company. It is engaged in the development of immunotherapeutic products for cancer and autoimmune disease. Their operations are based in Australia and Europe.

Latest IMM news

Currently there for this company. Visit our news hub for other news .